{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:19:58Z","timestamp":1793762398282,"version":"4.6.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67698-1","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:02:58Z","timestamp":1769076178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antibody-conjugated mesenchymal stromal cell drug delivery system for the treatment of autoimmune diseases in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-8599","authenticated-orcid":false,"given":"Qian","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-1705","authenticated-orcid":false,"given":"Yanni","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2394-0459","authenticated-orcid":false,"given":"Xiangfu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9356-2333","authenticated-orcid":false,"given":"Bing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-7312","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"67698_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-022-01059-y","volume":"7","author":"L Cheng","year":"2022","unstructured":"Cheng, L. et al. Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1\/2a, single-arm study. Signal Transduct. Target Ther. 7, 263 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"67698_CR2","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.amjmed.2015.11.001","volume":"129","author":"H Chen","year":"2016","unstructured":"Chen, H. et al. Treatment of Psoriasis with Mesenchymal Stem Cells. Am. J. Med. 129, e13\u2013e14 (2016).","journal-title":"Am. J. Med."},{"key":"67698_CR3","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.21037\/atm-21-5028","volume":"9","author":"D Yao","year":"2021","unstructured":"Yao, D. et al. Adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment for psoriasis: results of a single-arm pilot trial. Ann. Transl. Med. 9, 1653 (2021).","journal-title":"Ann. Transl. Med."},{"key":"67698_CR4","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/stem.68","volume":"27","author":"L Sun","year":"2009","unstructured":"Sun, L. et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27, 1421\u20131432 (2009).","journal-title":"Stem Cells"},{"key":"67698_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang, J. et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann. Rheum. Dis. 69, 1423\u20131429 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"67698_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/stcltm\/szad032","volume":"12","author":"Z Cao","year":"2023","unstructured":"Cao, Z. et al. Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared With Low-Dose Interleukin-2 in Systemic Lupus Erythematosus. Stem Cells Transl. Med. 12, 431\u2013443 (2023).","journal-title":"Stem Cells Transl. Med."},{"key":"67698_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.reth.2022.07.003","volume":"21","author":"A Alanazi","year":"2022","unstructured":"Alanazi, A., Alassiri, M., Jawdat, D. & Almalik, Y. Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis. Regen. Ther. 21, 201\u2013209 (2022).","journal-title":"Regen. Ther."},{"key":"67698_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","volume":"12","author":"GM Forbes","year":"2014","unstructured":"Forbes, G. M. et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn\u2019s disease refractory to biologic therapy. Clin. Gastroenterol. Hepatol. 12, 64\u201371 (2014).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"67698_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/codi.16239","volume":"24","author":"AL Lightner","year":"2022","unstructured":"Lightner, A. L. et al. A phase IB\/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis. Colorectal Dis. 24, 1358\u20131370 (2022).","journal-title":"Colorectal Dis."},{"key":"67698_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/apt.13864","volume":"45","author":"C Gregoire","year":"2017","unstructured":"Gregoire, C. et al. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Aliment Pharm. Ther. 45, 205\u2013221 (2017).","journal-title":"Aliment Pharm. Ther."},{"key":"67698_CR11","doi-asserted-by":"publisher","first-page":"631291","DOI":"10.3389\/fimmu.2021.631291","volume":"12","author":"JJ Hwang","year":"2021","unstructured":"Hwang, J. J., Rim, Y. A., Nam, Y. & Ju, J. H. Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis. Front. Immunol. 12, 631291 (2021).","journal-title":"Front. Immunol."},{"key":"67698_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.biopha.2018.11.056","volume":"109","author":"M Ghoryani","year":"2019","unstructured":"Ghoryani, M. et al. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed. Pharmacother. 109, 1834\u20131840 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"67698_CR13","doi-asserted-by":"publisher","first-page":"e2305116","DOI":"10.1002\/advs.202305116","volume":"11","author":"C Li","year":"2024","unstructured":"Li, C. et al. Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy. Adv. Sci. 11, e2305116 (2024).","journal-title":"Adv. Sci."},{"key":"67698_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"Corcione, A. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367\u2013372 (2006).","journal-title":"Blood"},{"key":"67698_CR15","doi-asserted-by":"publisher","unstructured":"Shen, Z. W. et al. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front. Immunol. 12, https:\/\/doi.org\/10.3389\/fimmu.2021.749192 (2021).","DOI":"10.3389\/fimmu.2021.749192"},{"key":"67698_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","volume":"41","author":"N Song","year":"2020","unstructured":"Song, N., Scholtemeijer, M. & Shah, K. Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharm. Sci. 41, 653\u2013664 (2020).","journal-title":"Trends Pharm. Sci."},{"key":"67698_CR17","doi-asserted-by":"publisher","unstructured":"Ra, J. C. et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J. Transl. Med. 9 https:\/\/doi.org\/10.1186\/1479-5876-9-181 (2011).","DOI":"10.1186\/1479-5876-9-181"},{"key":"67698_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12272-012-0201-0","volume":"35","author":"HS Hong","year":"2012","unstructured":"Hong, H. S., Kim, Y. H. & Son, Y. Perspectives on mesenchymal stem cells: tissue repair, immune modulation, and tumor homing. Arch. Pharmacal Res. 35, 201\u2013211 (2012).","journal-title":"Arch. Pharmacal Res."},{"key":"67698_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/scd.2004.13.463","volume":"13","author":"NS El-Badri","year":"2004","unstructured":"El-Badri, N. S., Maheshwari, A. & Sanberg, P. R. Mesenchymal stem cells in autoimmune disease. Stem Cells Dev. 13, 463\u2013472 (2004).","journal-title":"Stem Cells Dev."},{"key":"67698_CR20","doi-asserted-by":"publisher","unstructured":"Berglund, A. K., Fortier, L. A., Antczak, D. F. & Schnabel, L. V. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res. Ther. 8 https:\/\/doi.org\/10.1186\/s13287-017-0742-8 (2017).","DOI":"10.1186\/s13287-017-0742-8"},{"key":"67698_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915X689622","volume":"25","author":"T Squillaro","year":"2016","unstructured":"Squillaro, T., Peluso, G. & Galderisi, U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 25, 829\u2013848 (2016).","journal-title":"Cell Transplant."},{"key":"67698_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13287-017-0552-z","volume":"8","author":"A Bl\u00e1zquez-Prunera","year":"2017","unstructured":"Bl\u00e1zquez-Prunera, A., D\u00edez, J. M., Gajardo, R. & Grancha, S. Human mesenchymal stem cells maintain their phenotype, multipotentiality, and genetic stability when cultured using a defined xeno-free human plasma fraction. Stem Cell Res Ther. 8, 103 (2017).","journal-title":"Stem Cell Res Ther."},{"key":"67698_CR23","doi-asserted-by":"publisher","first-page":"E184","DOI":"10.1182\/blood-2010-10-311464","volume":"118","author":"D Sarkar","year":"2011","unstructured":"Sarkar, D. et al. Engineered cell homing. Blood 118, E184\u2013E191 (2011).","journal-title":"Blood"},{"key":"67698_CR24","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1021\/nn4062726","volume":"8","author":"XL Huang","year":"2014","unstructured":"Huang, X. L. et al. Design considerations of iron-based nanoclusters for noninvasive tracking of mesenchymal stem cell homing. Acs Nano 8, 4403\u20134414 (2014).","journal-title":"Acs Nano"},{"key":"67698_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.isci.2019.05.004","volume":"15","author":"M Ullah","year":"2019","unstructured":"Ullah, M., Liu, D. D. & Thakor, A. S. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience 15, 421\u2013438 (2019).","journal-title":"iScience"},{"key":"67698_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02822-5","volume":"19","author":"N Cuesta-Gomez","year":"2021","unstructured":"Cuesta-Gomez, N., Graham, G. J. & Campbell, J. D. M. Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells. J. Transl. Med. 19, 156 (2021).","journal-title":"J. Transl. Med."},{"key":"67698_CR27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau, J. & Sens\u00e9b\u00e9, L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22, 824\u2013833 (2018).","journal-title":"Cell Stem Cell"},{"key":"67698_CR28","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.ymthe.2020.02.014","volume":"28","author":"NR Dhoke","year":"2020","unstructured":"Dhoke, N. R., Kaushik, K. & Das, A. Cxcr6-based mesenchymal stem cell gene therapy potentiates skin regeneration in murine diabetic wounds. Mol. Ther. 28, 1314\u20131326 (2020).","journal-title":"Mol. Ther."},{"key":"67698_CR29","doi-asserted-by":"publisher","unstructured":"Kuang, S. H. et al. CCR2-engineered mesenchymal stromal cells accelerate diabetic wound healing by restoring immunological homeostasis. Biomaterials 275 https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120963 (2021).","DOI":"10.1016\/j.biomaterials.2021.120963"},{"key":"67698_CR30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41434-018-0041-8","volume":"25","author":"W Wei","year":"2018","unstructured":"Wei, W., Huang, Y., Li, D., Gou, H. F. & Wang, W. Improved therapeutic potential of MSCs by genetic modification. Gene Ther. 25, 538\u2013547 (2018).","journal-title":"Gene Ther."},{"key":"67698_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun, Y. V. & Goldmacher, V. S. Cell killing by antibody-drug conjugates. Cancer Lett. 255, 232\u2013240 (2007).","journal-title":"Cancer Lett."},{"key":"67698_CR32","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","volume":"27","author":"AW Tolcher","year":"2016","unstructured":"Tolcher, A. W. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann. Oncol. 27, 2168\u20132172 (2016).","journal-title":"Ann. Oncol."},{"key":"67698_CR33","doi-asserted-by":"publisher","unstructured":"Fu, Z. W., Li, S. J., Han, S. F., Shi, C. & Zhang, Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target. Ther. 7 https:\/\/doi.org\/10.1038\/s41392-022-00947-7 (2022).","DOI":"10.1038\/s41392-022-00947-7"},{"key":"67698_CR34","doi-asserted-by":"publisher","unstructured":"Raphael, I., Joern, R. R. & Forsthuber, T. G. Memory CD4+ T Cells in immunity and autoimmune diseases. Cells 9 https:\/\/doi.org\/10.3390\/cells9030531 (2020).","DOI":"10.3390\/cells9030531"},{"key":"67698_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1517\/14728222.2013.843669","volume":"18","author":"JW Yan","year":"2014","unstructured":"Yan, J. W. et al. Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases. Expert Opin. Ther. Tar. 18, 29\u201341 (2014).","journal-title":"Expert Opin. Ther. Tar."},{"key":"67698_CR36","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","volume":"8","author":"NJ Wilson","year":"2007","unstructured":"Wilson, N. J. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8, 950\u2013957 (2007).","journal-title":"Nat. Immunol."},{"key":"67698_CR37","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1172\/JCI28508","volume":"116","author":"Y Iwakura","year":"2006","unstructured":"Iwakura, Y. & Ishigame, H. The IL-23\/IL-17 axis in inflammation. J. Clin. Investig. 116, 1218\u20131222 (2006).","journal-title":"J. Clin. Investig."},{"key":"67698_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05450-x","volume":"22","author":"H Hu","year":"2024","unstructured":"Hu, H., Li, H., Li, R., Liu, P. & Liu, H. Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17\/Treg balance. J. Transl. Med. 22, 663 (2024).","journal-title":"J. Transl. Med."},{"key":"67698_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ni.1610","volume":"9","author":"N Manel","year":"2008","unstructured":"Manel, N., Unutmaz, D. & Littman, D. R. The differentiation of human TH-17 cells requires transforming growth factor-\u03b2 and induction of the nuclear receptor ROR\u03b3t. Nat. Immunol. 9, 641\u2013649 (2008).","journal-title":"Nat. Immunol."},{"key":"67698_CR40","doi-asserted-by":"publisher","unstructured":"Ma, S. Y. et al. ROR\u03b3t phosphorylation protects against T cell-mediated inflammation. Cell Rep. 38 https:\/\/doi.org\/10.1016\/j.celrep.2022.110520 (2022).","DOI":"10.1016\/j.celrep.2022.110520"},{"key":"67698_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/cpdd.1377","volume":"13","author":"CS Maier","year":"2024","unstructured":"Maier, C. S. et al. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis. Clin. Pharm. Drug Dev. 13, 474\u2013484 (2024).","journal-title":"Clin. Pharm. Drug Dev."},{"key":"67698_CR42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/13543776.2019.1655541","volume":"29","author":"NN Sun","year":"2019","unstructured":"Sun, N. N., Guo, H. M. & Wang, Y. H. Retinoic acid receptor-related orphan receptor gamma-t (ROR\u03b3t) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present). Expert Opin. Ther. Pat. 29, 663\u2013674 (2019).","journal-title":"Expert Opin. Ther. Pat."},{"key":"67698_CR43","doi-asserted-by":"publisher","first-page":"e2412253","DOI":"10.1002\/adma.202412253","volume":"36","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. Engineered enucleated mesenchymal stem cells regulating immune microenvironment and promoting wound healing. Adv. Mater. 36, e2412253 (2024).","journal-title":"Adv. Mater."},{"key":"67698_CR44","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1002\/anie.201601123","volume":"55","author":"PR Wratil","year":"2016","unstructured":"Wratil, P. R., Horstkorte, R. & Reutter, W. Metabolic Glycoengineering with N-Acyl Side Chain Modified Mannosamines. Angew. Chem. Int Ed. Engl. 55, 9482\u20139512 (2016).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"67698_CR45","doi-asserted-by":"publisher","unstructured":"Beccari, M. V. et al. Ibalizumab, a novel monoclonal antibody for the management of multidrug- resistant HIV-1 infection. Antimicrob. Agents Chemother. 63 https:\/\/doi.org\/10.1128\/aac.00110-19 (2019).","DOI":"10.1128\/aac.00110-19"},{"key":"67698_CR46","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/17460441.2021.1948833","volume":"16","author":"C Gege","year":"2021","unstructured":"Gege, C. Retinoic acid-related orphan receptor gamma t (ROR\u03b3t) inverse agonists\/antagonists for the treatment of inflammatory diseases - where are we presently? Expert Opin. Drug Discov. 16, 1517\u20131535 (2021).","journal-title":"Expert Opin. Drug Discov."},{"key":"67698_CR47","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/ced\/llae152","volume":"49","author":"S Tyring","year":"2024","unstructured":"Tyring, S. et al. Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial. Clin. Exp. Dermatol. 49, 1347\u20131355 (2024).","journal-title":"Clin. Exp. Dermatol."},{"key":"67698_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.plefa.2006.06.004","volume":"75","author":"M Weinreb","year":"2006","unstructured":"Weinreb, M. et al. Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity. Prostaglandins Leukotrienes Essent. Fat. Acids 75, 81\u201390 (2006).","journal-title":"Prostaglandins Leukotrienes Essent. Fat. Acids"},{"key":"67698_CR49","doi-asserted-by":"publisher","unstructured":"Jiang, N. Z. et al. Fibroblast growth factor 2 enhances BMSC stemness through ITGA2-dependent PI3K\/AKT pathway activation. J. Cell. Physiol. 239 https:\/\/doi.org\/10.1002\/jcp.31423 (2024).","DOI":"10.1002\/jcp.31423"},{"key":"67698_CR50","doi-asserted-by":"publisher","unstructured":"Jia, H. Y. et al. Lenalidomide attenuates IMQ-induced inflammation in a mouse model of psoriasis. Biomed. Pharmacother. 156, https:\/\/doi.org\/10.1016\/j.biopha.2022.113883 (2022).","DOI":"10.1016\/j.biopha.2022.113883"},{"key":"67698_CR51","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/art.24405","volume":"60","author":"MA Gonz\u00e1lez","year":"2009","unstructured":"Gonz\u00e1lez, M. A., Gonzalez-Rey, E., Rico, L., B\u00fcscher, D. & Delgado, M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 60, 1006\u20131019 (2009).","journal-title":"Arthritis Rheum."},{"key":"67698_CR52","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.molimm.2018.07.011","volume":"101","author":"X-j Xie","year":"2018","unstructured":"Xie, X. -j. et al. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing \u03b3\u03b4 T cells. Mol. Immunol. 101, 386\u2013395 (2018).","journal-title":"Mol. Immunol."},{"key":"67698_CR53","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269\u20131275 (2007).","journal-title":"Nat. Protoc."},{"key":"67698_CR54","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E. & Barker, J. N. W. N. Psoriasis.  Lancet 397, 1301\u20131315 (2021).","journal-title":"Lancet"},{"key":"67698_CR55","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis.  Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"67698_CR56","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.berh.2019.01.006","volume":"32","author":"A Lerner","year":"2018","unstructured":"Lerner, A., Neidh\u00f6fer, S., Reuter, S. & Matthias, T. MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. 32, 550\u2013562 (2018).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"67698_CR57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich, K. et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N. Engl. J. Med 385, 142\u2013152 (2021).","journal-title":"N. Engl. J. Med"},{"key":"67698_CR58","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/acsmedchemlett.7b00476","volume":"9","author":"YH Wang","year":"2018","unstructured":"Wang, Y. H. et al. From ROR\u03b3t Agonist to Two Types of ROR\u03b3t Inverse Agonists. ACS Med. Chem. Lett. 9, 120\u2013124 (2018).","journal-title":"ACS Med. Chem. Lett."},{"key":"67698_CR59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-physiol-021909-135917","volume":"72","author":"PX Huang","year":"2010","unstructured":"Huang, P. X., Chandra, V. & Rastinejad, F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol. 72, 247\u2013272 (2010).","journal-title":"Annu. Rev. Physiol."},{"key":"67698_CR60","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41423-024-01218-x","volume":"21","author":"D Ohara","year":"2024","unstructured":"Ohara, D., Takeuchi, Y. & Hirota, K. Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells. Cell. Mol. Immunol. 21, 1183\u20131200 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"67698_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40744-017-0086-y","volume":"4","author":"H Tahir","year":"2017","unstructured":"Tahir, H. et al. Secukinumab in Active rheumatoid arthritis after anti-TNF\u03b1 therapy: a randomized, double-blind placebo-controlled Phase 3 Study. Rheumatol. Ther. 4, 475\u2013488 (2017).","journal-title":"Rheumatol. Ther."},{"key":"67698_CR62","doi-asserted-by":"publisher","unstructured":"Murata, M. & Teshima, T. Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem cell products. Front. Immunol. 12 https:\/\/doi.org\/10.3389\/fimmu.2021.724380 (2021).","DOI":"10.3389\/fimmu.2021.724380"},{"key":"67698_CR63","doi-asserted-by":"publisher","unstructured":"Liang, J. H. et al. Incidence of collagen-induced arthritis is elevated by a high-fat diet without influencing body weight in mice. RMD Open 10 https:\/\/doi.org\/10.1136\/rmdopen-2023-003869 (2024).","DOI":"10.1136\/rmdopen-2023-003869"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67698-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:12:33Z","timestamp":1769213553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67698-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67698"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67698-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: Q.X., Y.N.S., J.H.L., and Y.W. are named as inventors on a granted patent (ZL202411354633.2) filed by Shenzhen Institutes of Advanced Technology, which relates to the technology described in this manuscript. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"830"}}